Sarepta Net Debt from 2010 to 2025

SRPT Stock

USD 74.10 0.65 0.88%

Sarepta Therapeutics Net Debt yearly trend continues to be comparatively stable with very little volatility. Net Debt is likely to outpace its year average in 2025. Net Debt is the total debt of Sarepta Therapeutics minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

1996-12-31

Previous Quarter

1.2 B

Current Value

226.6 M

Quarterly Volatility

318.7 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Sarepta Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sarepta Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 39.6 M, Interest Expense of 10.6 M or Selling General Administrative of 585.8 M, as well as many indicators such as Price To Sales Ratio of 5.77, Dividend Yield of 0.0 or PTB Ratio of 6.75. Sarepta financial statements analysis is a perfect complement when working with Sarepta Therapeutics Valuation or Volatility modules.

Check out the analysis of Sarepta Therapeutics Correlation against competitors.

For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.

Latest Sarepta Therapeutics' Net Debt Growth Pattern

Below is the plot of the Net Debt of Sarepta Therapeutics over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Sarepta Therapeutics' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sarepta Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Sarepta Net Debt Regression Statistics

	Arithmetic Mean	(16,158,916)
	Coefficient Of Variation	(2,658)
	Mean Deviation	278,680,230
	Median	(56,906,000)
	Standard Deviation	429,514,318
	Sample Variance	184482.5T
	Range	1.9B
	R-Value	0.32
	Mean Square Error	176956.5T
	R-Squared	0.10
	Significance	0.22
	Slope	29,197,462
	Total Sum of Squares	2767238.2T

Sarepta Net Debt History

	2025	237.9 M
	2024	226.6 M
	2023	968.4 M
	2022	650.6 M
	2021	-977.5 M
	2020	-429.8 M
	2019	-105.5 M

Other Fundumenentals of Sarepta Therapeutics

Net Debt To E B I T D A

Sarepta Therapeutics Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Net Receivables	Current Deferred Revenue	Long Term Debt	Short Term Debt	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.86	0.27	-0.97	0.92	0.49	0.97	1.0	0.84	-0.29	0.98	0.87	0.9	0.96	0.75	0.54	0.99	0.99	0.93	0.93	0.59	0.92	0.94
Total Stockholder Equity	0.86		0.13	-0.77	0.83	0.3	0.72	0.85	0.88	-0.33	0.81	0.81	0.72	0.71	0.7	0.66	0.82	0.86	0.82	0.77	0.8	0.69	0.75
Net Debt	0.27	0.13		-0.41	0.42	0.71	0.31	0.24	0.39	0.01	0.38	0.47	0.16	0.32	-0.23	-0.28	0.26	0.26	0.24	0.3	0.13	0.15	0.32
Retained Earnings	-0.97	-0.77	-0.41		-0.91	-0.59	-0.97	-0.96	-0.84	0.34	-0.98	-0.86	-0.84	-0.96	-0.66	-0.44	-0.97	-0.97	-0.9	-0.93	-0.47	-0.9	-0.94
Accounts Payable	0.92	0.83	0.42	-0.91		0.37	0.87	0.89	0.9	-0.24	0.94	0.97	0.88	0.82	0.62	0.26	0.89	0.89	0.82	0.91	0.67	0.85	0.92
Short Term Investments	0.49	0.3	0.71	-0.59	0.37		0.53	0.5	0.45	-0.22	0.51	0.33	0.21	0.58	0.18	0.34	0.49	0.52	0.52	0.39	0.04	0.35	0.35
Total Liab	0.97	0.72	0.31	-0.97	0.87	0.53		0.97	0.75	-0.25	0.97	0.82	0.9	0.99	0.71	0.43	0.98	0.96	0.89	0.91	0.45	0.95	0.93
Total Current Assets	1.0	0.85	0.24	-0.96	0.89	0.5	0.97		0.83	-0.3	0.98	0.85	0.89	0.96	0.76	0.57	0.99	0.99	0.93	0.91	0.58	0.92	0.92
Intangible Assets	0.84	0.88	0.39	-0.84	0.9	0.45	0.75	0.83		-0.35	0.83	0.89	0.7	0.71	0.62	0.41	0.81	0.83	0.73	0.81	0.58	0.71	0.79
Common Stock	-0.29	-0.33	0.01	0.34	-0.24	-0.22	-0.25	-0.3	-0.35		-0.28	-0.18	-0.19	-0.25	-0.2	-0.35	-0.26	-0.33	-0.26	-0.21	-0.14	-0.2	-0.2
Property Plant Equipment	0.98	0.81	0.38	-0.98	0.94	0.51	0.97	0.98	0.83	-0.28		0.9	0.9	0.95	0.69	0.43	0.98	0.98	0.92	0.94	0.58	0.92	0.96
Net Receivables	0.87	0.81	0.47	-0.86	0.97	0.33	0.82	0.85	0.89	-0.18	0.9		0.87	0.77	0.54	0.17	0.84	0.84	0.74	0.89	0.71	0.8	0.92
Current Deferred Revenue	0.9	0.72	0.16	-0.84	0.88	0.21	0.9	0.89	0.7	-0.19	0.9	0.87		0.84	0.71	0.26	0.88	0.85	0.75	0.89	0.63	0.94	0.91
Long Term Debt	0.96	0.71	0.32	-0.96	0.82	0.58	0.99	0.96	0.71	-0.25	0.95	0.77	0.84		0.65	0.5	0.98	0.95	0.9	0.87	0.42	0.89	0.91
Short Term Debt	0.75	0.7	-0.23	-0.66	0.62	0.18	0.71	0.76	0.62	-0.2	0.69	0.54	0.71	0.65		0.63	0.74	0.73	0.74	0.71	0.48	0.8	0.64
Net Tangible Assets	0.54	0.66	-0.28	-0.44	0.26	0.34	0.43	0.57	0.41	-0.35	0.43	0.17	0.26	0.5	0.63		0.53	0.59	0.64	0.33	0.35	0.35	0.29
Long Term Debt Total	0.99	0.82	0.26	-0.97	0.89	0.49	0.98	0.99	0.81	-0.26	0.98	0.84	0.88	0.98	0.74	0.53		0.98	0.92	0.92	0.53	0.92	0.94
Capital Surpluse	0.99	0.86	0.26	-0.97	0.89	0.52	0.96	0.99	0.83	-0.33	0.98	0.84	0.85	0.95	0.73	0.59	0.98		0.94	0.9	0.57	0.89	0.92
Short Long Term Debt	0.93	0.82	0.24	-0.9	0.82	0.52	0.89	0.93	0.73	-0.26	0.92	0.74	0.75	0.9	0.74	0.64	0.92	0.94		0.84	0.6	0.81	0.84
Net Invested Capital	0.93	0.77	0.3	-0.93	0.91	0.39	0.91	0.91	0.81	-0.21	0.94	0.89	0.89	0.87	0.71	0.33	0.92	0.9	0.84		0.59	0.95	0.97
Long Term Investments	0.59	0.8	0.13	-0.47	0.67	0.04	0.45	0.58	0.58	-0.14	0.58	0.71	0.63	0.42	0.48	0.35	0.53	0.57	0.6	0.59		0.47	0.54
Net Working Capital	0.92	0.69	0.15	-0.9	0.85	0.35	0.95	0.92	0.71	-0.2	0.92	0.8	0.94	0.89	0.8	0.35	0.92	0.89	0.81	0.95	0.47		0.92
Capital Stock	0.94	0.75	0.32	-0.94	0.92	0.35	0.93	0.92	0.79	-0.2	0.96	0.92	0.91	0.91	0.64	0.29	0.94	0.92	0.84	0.97	0.54	0.92

Click cells to compare fundamentals

About Sarepta Therapeutics Financial Statements

Sarepta Therapeutics shareholders use historical fundamental indicators, such as Net Debt, to determine how well the company is positioned to perform in the future. Although Sarepta Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Sarepta Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Sarepta Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Net Debt	226.6 M	237.9 M
Net Debt To EBITDA	0.72	0.68

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sarepta Net Debt from 2010 to 2025

Latest Sarepta Therapeutics' Net Debt Growth Pattern

Sarepta Net Debt Regression Statistics

Sarepta Net Debt History

Other Fundumenentals of Sarepta Therapeutics

Sarepta Therapeutics Net Debt component correlations

About Sarepta Therapeutics Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Sarepta Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY